Stay updated with breaking news from Drug Development Unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.
/PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) today released a case study outlining the evolution of a newly FDA-approved...
/PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement...
Dr Dearbhaile Collins is honoured for her cancer research work
Fort Myers, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is among the...